港鐵(00066.HK)旗下MTR Lab去年審閱逾千份投資提案 至今完成6個合作項目
港鐵(00066.HK)旗下全資子公司MTR Lab正式運作兩年,去年已審閱超過1,000份投資提案與機會,至今累計完成六個合作項目。MTR Lab董事總經理陳定邦表示,目標為母公司創造戰略價值,在鐵路科技、房地產和建築科技、一體化出行服務等六個行業領域與母公司產生協同效應。
陳定邦表示,主要關注已完成A輪融資的創科公司,因出品較穩定且有增長空間,發展初期階段的公司也留意其成長情況,但不會積極尋求合作;目前有數個項目可望成事,將適時公布。他又對大灣區的項目感興趣,指出區內有眾多創科公司,希望達成合作,引入革新科技幫助創科公司成長。
MTR Lab主要透過科技投資支持社區可持續發展,聚焦智慧城市及可持續發展兩大主題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.